Loading…
Loading…
RDNT does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for RDNT and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for RDNT and 80,000+ other tickers.
See exactly how RDNT's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for RDNT and 80,000+ other tickers.
RadNet, Inc. operates as a prominent healthcare services company specializing in outpatient diagnostic imaging across the United States. Their comprehensive offerings span a broad spectrum of advanced imaging techniques, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, and general diagnostic radiology, along with various specialized procedures. Beyond direct patient services, the company also plays a significant role in developing and marketing specialized computerized systems for the…
RadNet (NASDAQ: RDNT - Get Free Report) and Joint (NASDAQ: JYNT - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings. Valuation and Earnings This table compares RadNet and Joint"s revenue,
SOMERVILLE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today announced new findings published in European Radiology supporting that AI applications within DeepHealth's Prostate MR Solution1 could help clinicians decide more confidently which men may need a prostate biopsy, particularly when MRI findings are uncertain.2 Prostate cancer is the second most commonly diagnosed cancer among men worldwide, with an estimated 1.55 million new cases in 2024.3 MRI helps clinicians assess whether prostate cancer may be present, but some findings remain uncertain.4 A biopsy involves collecting small tissue samples to check for cancer and, if found, assess its grade.
New program introduces students and young adults to careers in radiology through mentorship, digital experiences and hands-on learning. OWINGS MILLS, Md.
Engineers Gate Manager LP acquired a new position in RadNet, Inc. (NASDAQ: RDNT) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 8,100 shares of the medical research company's stock, valued at approximately $500,000. A number of other
RadNet, Inc. (RDNT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript